| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
,25-Dihydroxyvitamin D3 in Promyelocytic NB4 Leukemia Cells: A Structure-Function Study1
Department of Biochemistry (X.S., J.E.B., A.W.N.), Division of Biomedical Sciences (A.W.N.), and the Department of Chemistry (W.H.O.), University of California, Riverside, California 92521
Address all correspondence and requests for reprints to: Prof. Anthony W. Norman, Department of Biochemistry, University of California, Riverside, California 92521. E-mail: Norman{at}ucrac1.ucr.edu
Recent studies have shown that 1
,25-dihydroxyvitamin D3
[1
,25-(OH)2D3] actions in cell growth and
differentiation are mediated by both its nuclear receptor
(VDRnuc) and its rapid membrane-related effects. In the
present study, we investigated the effect of
1
,25-(OH)2D3 on p42mapk
phosphorylation using human acute promyelocytic leukemia cells (NB4).
1
,25-(OH)2D3 (10-8
M) significantly increased p42mapk
phosphorylation in a time- and dose-dependent manner, with the earliest
response detectable at 30 sec. Because
1
,25-(OH)2D3 is a conformationally flexible
molecule, we have used a series of conformationally locked
(6-s-cis vs. 6-s-trans) analogs to
evaluate which shape is optimal for activation. Four
6-s-cis-locked analogs (HF, JM, JN, and JP) and two
6-s-trans-locked analog (JB and JD) were studied. HF,
JM, JN, and JP all increased p42mapk phosphorylation at 1
and 5 min (10-8 M), but JB and JD had little
effect. Analog HL [1ß,25-(OH)2D3], a
specific antagonist for only the rapid effects of
1
,25-(OH)2D3, attenuated
1
,25-(OH)2D3-induced p42mapk
phosphorylation 6590%. To assess the potential involvement of the
VDRnuc in mediating the analogs action, the relative
abilities of the analogs to compete with
[3H]1
,25-(OH)2D3 for binding
in vitro to the VDRnuc of NB4 cells was
measured. All 6-s-cis analogs bound poorly to
VDRnuc (relative competitive index, 0.52%) compared with
1
,25-(OH)2D3 (relative competitive index,
100%). The present studies demonstrate for the first time that in NB4
cells 1
,25-(OH)2D3 rapidly activates the
p42mapk pathway, and that this effect can be selectively
mediated by analogs that can assume a 6-s-cis
conformation.
This article has been cited by other articles:
![]() |
M. T. Mizwicki and A. W. Norman The Vitamin D Sterol-Vitamin D Receptor Ensemble Model Offers Unique Insights into Both Genomic and Rapid-Response Signaling Sci. Signal., June 16, 2009; 2(75): re4 - re4. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang and G. P. Studzinski The Requirement for and Changing Composition of the Activating Protein-1 Transcription Factor during Differentiation of Human Leukemia HL60 Cells Induced by 1,25-Dihydroxyvitamin D3. Cancer Res., April 15, 2006; 66(8): 4402 - 4409. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Dusso, A. J. Brown, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, July 1, 2005; 289(1): F8 - F28. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ochiai, D. Miura, H. Eguchi, S. Ohara, K. Takenouchi, Y. Azuma, T. Kamimura, A. W. Norman, and S. Ishizuka Molecular Mechanism of the Vitamin D Antagonistic Actions of (23S)-25-Dehydro-1{alpha}-Hydroxyvitamin D3-26,23-Lactone Depends on the Primary Structure of the Carboxyl-Terminal Region of the Vitamin D Receptor Mol. Endocrinol., May 1, 2005; 19(5): 1147 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Vertino, C. M. Bula, J.-R. Chen, M. Almeida, L. Han, T. Bellido, S. Kousteni, A. W. Norman, and S. C. Manolagas Nongenotropic, Anti-Apoptotic Signaling of 1{alpha},25(OH)2-Vitamin D3 and Analogs through the Ligand Binding Domain of the Vitamin D Receptor in Osteoblasts and Osteocytes: MEDIATION BY Src, PHOSPHATIDYLINOSITOL 3-, AND JNK KINASES J. Biol. Chem., April 8, 2005; 280(14): 14130 - 14137. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Narayanan, V. A. T. Sepulveda, M. Falzon, and N. L. Weigel The Functional Consequences of Cross-talk between the Vitamin D Receptor and ERK Signaling Pathways Are Cell-specific J. Biol. Chem., November 5, 2004; 279(45): 47298 - 47310. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Huhtakangas, C. J. Olivera, J. E. Bishop, L. P. Zanello, and A. W. Norman The Vitamin D Receptor Is Present in Caveolae-Enriched Plasma Membranes and Binds 1{alpha},25(OH)2-Vitamin D3 in Vivo and in Vitro Mol. Endocrinol., November 1, 2004; 18(11): 2660 - 2671. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Mizwicki, D. Keidel, C. M. Bula, J. E. Bishop, L. P. Zanello, J.-M. Wurtz, D. Moras, and A. W. Norman Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1{alpha},25(OH)2-vitamin D3 signaling PNAS, August 31, 2004; 101(35): 12876 - 12881. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-M. Nguyen, M. Lieberherr, J. Fritsch, H. Guillozo, M. L. Alvarez, Z. Fitouri, F. Jehan, and M. Garabedian The Rapid Effects of 1,25-Dihydroxyvitamin D3 Require the Vitamin D Receptor and Influence 24-Hydroxylase Activity: STUDIES IN HUMAN SKIN FIBROBLASTS BEARING VITAMIN D RECEPTOR MUTATIONS J. Biol. Chem., February 27, 2004; 279(9): 7591 - 7597. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Zanello and A. W. Norman Rapid modulation of osteoblast ion channel responses by 1{alpha},25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor PNAS, February 10, 2004; 101(6): 1589 - 1594. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. M. Sutton and P. N. MacDonald Vitamin D: More Than a "Bone-a-Fide" Hormone Mol. Endocrinol., May 1, 2003; 17(5): 777 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Galbiati, L. Polastri, S. Gregori, M. Freschi, M. Casorati, U. Cavallaro, P. Fiorina, F. Bertuzzi, A. Zerbi, G. Pozza, et al. Antitumorigenic and Antiinsulinogenic Effects of Calcitriol on Insulinoma Cells and Solid {beta}-Cell Tumors Endocrinology, October 1, 2002; 143(10): 4018 - 4030. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Schwartz, H. Ehland, V. L. Sylvia, D. Larsson, R. R. Hardin, V. Bingham, D. Lopez, D. D. Dean, and B. D. Boyan 1{alpha},25-Dihydroxyvitamin D3 and 24R,25-Dihydroxyvitamin D3 Modulate Growth Plate Chondrocyte Physiology via Protein Kinase C-Dependent Phosphorylation of Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Endocrinology, July 1, 2002; 143(7): 2775 - 2786. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Jensen, M. W. Madsen, J. Lukas, L. Binderup, and J. Bartek Inhibitory Effects of 1{alpha},25-Dihydroxyvitamin D3 on the G1-S Phase-Controlling Machinery Mol. Endocrinol., August 1, 2001; 15(8): 1370 - 1380. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishizuka, D. Miura, K. Ozono, M. Chokki, H. Mimura, and A. W. Norman Antagonistic Actions in Vivo of (23S)-25-Dehydro-1{{alpha}}-Hydroxyvitamin D3-26,23-Lactone on Calcium Metabolism Induced by 1{{alpha}},25-Dihydroxyvitamin D3 Endocrinology, January 1, 2001; 142(1): 59 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Scaglione-Sewell, M. Bissonnette, S. Skarosi, C. Abraham, and T. A. Brasitus A Vitamin D3 Analog Induces a G1-Phase Arrest in CaCo-2 Cells by Inhibiting Cdk2 and Cdk6: Roles of Cyclin E, p21Waf1, and p27Kip1 Endocrinology, November 1, 2000; 141(11): 3931 - 3939. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Falkenstein, A. W. Norman, and M. Wehling Mannheim Classification of Nongenomically Initiated (Rapid) Steroid Action(s) J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2072 - 2075. [Abstract] [Full Text] |
||||
![]() |
D. M. Berry and K. A. Meckling-Gill Vitamin D Analogs, 20-Epi-22-Oxa-24a,26a,27a,-Trihomo-1{alpha},25(OH)2-Vitamin D3, 1,24(OH)2-22-Ene-24-Cyclopropyl-Vitamin D3 and 1{alpha},25(OH)2-Lumisterol3 Prime NB4 Leukemia Cells for Monocytic Differentiation via Nongenomic Signaling Pathways, Involving Calcium and Calpain Endocrinology, October 1, 1999; 140(10): 4779 - 4788. [Abstract] [Full Text] |
||||
![]() |
D. Miura, K. Manabe, K. Ozono, M. Saito, Q. Gao, A. W. Norman, and S. Ishizuka Antagonistic Action of Novel 1alpha ,25-Dihydroxyvitamin D3-26,23-lactone Analogs on Differentiation of Human Leukemia Cells (HL-60) Induced by 1alpha ,25-Dihydroxyvitamin D3 J. Biol. Chem., June 4, 1999; 274(23): 16392 - 16399. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Song, H. M. Sheppard, A. W. Norman, and X. Liu Mitogen-activated Protein Kinase Is Involved in the Degradation of p53 Protein in the Bryostatin-1-induced Differentiation of the Acute Promyelocytic Leukemia NB4 Cell Line J. Biol. Chem., January 15, 1999; 274(3): 1677 - 1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Morelli, C. Buitrago, G. Vazquez, A. R. De Boland, and R. Boland Involvement of Tyrosine Kinase Activity in 1alpha ,25(OH)2-vitamin D3 Signal Transduction in Skeletal Muscle Cells J. Biol. Chem., November 10, 2000; 275(46): 36021 - 36028. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |